Jiangnan University

Qixiao Zhai

Gang Wang

Hao Zhang

Jianxin Zhao

Wenwei Lu

Fengwei Tian

Bo Yang

Shumao Cui

Daming Fan

Qiuxiang Zhang

Xiaoming Liu

Huizi Tan

Leilei Yu

Meiyi Zhang

Yuanda Song

Xinyang Liu

Xi Liang

Qingmin Kong

Zhifeng Fang

Zhexin Fan

Shunhe Wang

Bingyong Mao

Min Guo

Feng Hang

Wei Chen

The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms.CCFM1051,CCFM1052 andCCFM1053 of the present disclosure have high adsorption effect on PFOA, can significantly relieve liver oxidative stress damage and serum biochemical indicators caused by PFOA, spleen atrophy caused by PFOA exposure, imbalance of intestinal microorganisms caused by PFOA exposure and metabolic disorder of intestinal flora caused by PFOA exposure, significantly increase the content of acetic acid and propionic acid in the intestinal tract, increase the fecal water content and decrease first black stool defecation time of mice with constipation, improve proliferation and MafA gene expression of INS-1 cells under high glucose, have the potential to relieve PFOA-related diabetes, reduce occurrence of liver diseases, metabolic diseases and potential carcinogenicity, and have broad use prospects.

Multifunctionalcapable of relieving PFOA toxic effects and application thereof

Described is astrain for relieving rheumatoid arthritis and application thereof, belonging to the technical field of microorganisms. Described is astrain CCFM1078 possessing the effect of relieving rheumatoid arthritis, and shown to: promote secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; reduce joint thickness, clinical score, and incidence of rats with rheumatoid arthritis; decrease levels of the pro-inflammatory cytokines TNFα and IL-1β in the serum of rats with rheumatoid arthritis; regulate the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; decrease the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and reduce secretion of pro-inflammatory factor IL-6 from synovial cells.

Bifidobacterium breve capable of relieving rheumatoid arthritis and application thereof

The disclosure discloses a strain ofcapable of preventing and/or treatinginfection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain ofCCFM1118. TheCCFM1118 can inhibit, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of theCCFM1118 oncan reach 13.14 mm; and (2) theCCFM1118 can significantly reduce the adhesion ofto AGS cells. Therefore, theCCFM1118 has great application prospects in inhibiting(not for the purposes of disease diagnosis and treatment) and preparinginhibitors.

Strain ofcapable of preventing and/or treatinginfection

The disclosure discloseswith the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. Theof the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, thehas great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

with the ability to relieve atopic dermatitis and its application

The disclosure discloses a strain ofand application thereof in inhibiting, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain ofCCFM1119. TheCCFM1119 can prevent and/or treatinfection, specifically embodied in that: (1) theCCFM1119 can significantly relieve the gastrointestinal symptoms of patients withinfection; (2) theCCFM1119 can significantly reduce the amount of colonization ofin patients withinfection; and (3) theCCFM1119 can significantly increase the clearance rate ofin patients withinfection. Therefore,CCFM1119 has great application prospects in the preparation of products (such as food or medicine) for preventing and/or treatinginfection.

Strain ofand application thereof in inhibiting

The disclosure disclosesfor relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. TheCCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of theCCFM1020 for relieving endotoxin infection has broad application prospects.

for relieving endotoxin infection and application thereof

The disclosure disclosesfor relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. TheCCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of theCCFM1021 for relieving endotoxin infection has broad application prospects.

[object Object]

The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.

Probiotic mixed preparation with anti-influenza ability and application thereof

The invention provides a novel strain of cadmium-removingbacterium, CCFM8610, which has a good tolerance to acidic environments.CCFM8610 has a good tolerance to cadmium-containing medium and can effectively bind cadmium in vitro. Animal studies have shown that it can effectively reduce tissue cadmium accumulation and facilitate fecal cadmium excretion.CCFM8610 has a great potential to be used as an active ingredient in cadmium-removing pharmaceutical drugs and fermented foods.

TheCCFM8661 is tolerant to acid and lead ions in vitro which can tolerate lead ions solution with the initial concentration of 150 mg/L, and has a strong capability of binding lead ions, which can reduce the lead level in mice blood, liver, kidney and stomach, significantly improve antioxidant indicators and alleviate pathological symptoms of lead exposed mice.

Growing community of inventors

Wuxi, China

Qixiao Zhai